German HTA Queries Polivy Benefits Amid Lack Of Evidence

 
• By Francesca Bruce

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

German HTA Wants More HTA-appropriate evidence for Roche's Polivy • Source: Shutterstock

More from Europe

More from Geography